Surrozen (SRZN) Scheduled to Post Quarterly Earnings on Tuesday

Surrozen (NASDAQ:SRZN) will release its earnings data on Tuesday, April 2nd.

Surrozen Stock Down 35.7 %

SRZN stock traded down $5.61 during midday trading on Monday, reaching $10.10. The company’s stock had a trading volume of 221,890 shares, compared to its average volume of 16,547. Surrozen has a 52 week low of $4.50 and a 52 week high of $16.19. The stock has a market cap of $20.60 million, a PE ratio of -0.58 and a beta of 0.74. The business’s 50-day simple moving average is $11.65 and its 200-day simple moving average is $8.91.

Hedge Funds Weigh In On Surrozen

A number of hedge funds and other institutional investors have recently bought and sold shares of SRZN. Trustees of Columbia University in the City of New York bought a new position in shares of Surrozen during the fourth quarter worth $419,000. Morgan Stanley boosted its position in shares of Surrozen by 10,427.8% during the fourth quarter. Morgan Stanley now owns 528,179 shares of the company’s stock worth $307,000 after purchasing an additional 523,162 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Surrozen by 3.2% during the third quarter. Vanguard Group Inc. now owns 487,278 shares of the company’s stock worth $984,000 after purchasing an additional 15,299 shares in the last quarter. FMR LLC bought a new position in shares of Surrozen during the second quarter worth $744,000. Finally, Millennium Management LLC acquired a new stake in shares of Surrozen during the fourth quarter worth $72,000. 66.57% of the stock is owned by institutional investors.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.